Fibrovein

ApprovedSmall molecule

OOslo University Hospital

Fibrovein is one of 17 small molecule programs targeting Venous malformation. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous MalformationActive, not recruiting

Venous MalformationApproved

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Venous Malformation

#DrugCompanyPhaseTrials

Depo-Provera

Pfizer

Approved

1 2

Rapamycin

MMaastricht Radiation Oncology

Approved

1 3

Thalomid

Bristol-Myers Squibb

Phase 2

1 4

Cotellic

Roche

Phase 2

1 5

Eliquis

Bristol-Myers Squibb

Phase 2

1 6

Mekinist

Novartis

Phase 2

1 7

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 8

Rapamune

PPrism Pharmaceuticals

Phase 2

1 9

Fibrovein

OOslo University Hospital

Approved

1 10

Avastin

BBio-Thera Solutions

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Venous malformation1 trial

Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations

Unknown status·OOslo University Hospital·Phase 4·NCT01347294·135 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fibrovein. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fibrovein compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fibrovein. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oslo University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: OOslo University Hospital

Fibrovein

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Venous malformation1 trial

References

Drug Info

Quick Facts

Related News